Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. ADLs indicates activities of daily living; CES-D, Center for Epidemiologic Studies Depression scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.aParticipant may be ineligible for >1 reason.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale was used to measure self-reported pain while performing daily living activities in the last 48 hours due to knee osteoarthritis. Total scores range from 0 to 20; higher scores indicate greater pain. The estimates are based on the previously stated number of observations and multiply imputed values for the missing observations within each group adjusted for baseline body mass index, sex, and baseline values. P = .002 comparing the diet + exercise group with the diet group and exercise group. Error bars indicate 95% CIs.
eMethods. Knee joint load
eTable 1. Serious adverse events
eTable 2. Intention-to-treat completers-only analysis: unadjusted mean (95% CI) mechanistic and clinical outcomes at baseline (0), and 6 and 18-month follow-up by group and 18-month outcomes adjusted for gender, BMI, and baseline values
eTable 3. Intention-to-treat completers-only analysis: pairwise between group differences (mean and 95% CI) at 18-month follow-up for primary and secondary outcomes
eTable 4. Mean (95% CI) dose response to weight change with knee compressive force, IL-6, pain, and function independent of group assignment
eFigure. Mean (95% CI) month-by-month weight loss of the D and D+E groups
Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, Williamson JD, Carr JJ, Guermazi A, Loeser RF. Effects of Intensive Diet and Exercise on Knee Joint Loads, Inflammation, and Clinical Outcomes Among Overweight and Obese Adults With Knee OsteoarthritisThe IDEA Randomized Clinical Trial. JAMA. 2013;310(12):1263-1273. doi:10.1001/jama.2013.277669
Knee osteoarthritis (OA), a common cause of chronic pain and disability, has biomechanical and inflammatory origins and is exacerbated by obesity.
To determine whether a ≥10% reduction in body weight induced by diet, with or without exercise, would improve mechanistic and clinical outcomes more than exercise alone.
Design, Setting, and Participants
Single-blind, 18-month, randomized clinical trial at Wake Forest University between July 2006 and April 2011. The diet and exercise interventions were center-based with options for the exercise groups to transition to a home-based program. Participants were 454 overweight and obese older community-dwelling adults (age ≥55 years with body mass index of 27-41) with pain and radiographic knee OA.
Intensive diet-induced weight loss plus exercise, intensive diet-induced weight loss, or exercise.
Main Outcomes and Measures
Mechanistic primary outcomes: knee joint compressive force and plasma IL-6 levels; secondary clinical outcomes: self-reported pain (range, 0-20), function (range, 0-68), mobility, and health-related quality of life (range, 0-100).
Three hundred ninety-nine participants (88%) completed the study. Mean weight loss for diet + exercise participants was 10.6 kg (11.4%); for the diet group, 8.9 kg (9.5%); and for the exercise group, 1.8 kg (2.0%). After 18 months, knee compressive forces were lower in diet participants (mean, 2487 N; 95% CI, 2393 to 2581) compared with exercise participants (2687 N; 95% CI, 2590 to 2784, pairwise difference [Δ]exercise vs diet = 200 N; 95% CI, 55 to 345; P = .007). Concentrations of IL-6 were lower in diet + exercise (2.7 pg/mL; 95% CI, 2.5 to 3.0) and diet participants (2.7 pg/mL; 95% CI, 2.4 to 3.0) compared with exercise participants (3.1 pg/mL; 95% CI, 2.9 to 3.4; Δexercise vs diet + exercise = 0.39 pg/mL; 95% CI, −0.03 to 0.81; P = .007; Δexercise vs diet = 0.43 pg/mL; 95% CI, 0.01 to 0.85, P = .006). The diet + exercise group had less pain (3.6; 95% CI, 3.2 to 4.1) and better function (14.1; 95% CI, 12.6 to 15.6) than both the diet group (4.8; 95% CI, 4.3 to 5.2) and exercise group (4.7; 95% CI, 4.2 to 5.1, Δexercise vs diet + exercise = 1.02; 95% CI, 0.33 to 1.71; Ppain = .004; 18.4; 95% CI, 16.9 to 19.9; Δexercise vs diet + exercise, 4.29; 95% CI, 2.07 to 6.50; Pfunction < .001). The diet + exercise group (44.7; 95% CI, 43.4 to 46.0) also had better physical health-related quality of life scores than the exercise group (41.9; 95% CI, 40.5 to 43.2; Δexercise vs diet + exercise = −2.81; 95% CI, −4.76 to −0.86; P = .005).
Conclusions and Relevance
Among overweight and obese adults with knee OA, after 18 months, participants in the diet + exercise and diet groups had more weight loss and greater reductions in IL-6 levels than those in the exercise group; those in the diet group had greater reductions in knee compressive force than those in the exercise group.
clinicaltrials.gov Identifier: NCT00381290
Osteoarthritis (OA) is the leading cause of chronic disability among older adults. Knee OA is the most frequent cause of mobility dependency and diminished quality of life,1 and obesity is a major risk factor for knee OA.2 Current treatments for knee OA are inadequate; of patients treated pharmacologically, only about half experience a 30% pain reduction, usually without improved function.3 The few studies of long-term weight loss in obese adults with knee OA showed equally modest improvements.4,5
Knee OA is considered an active disease process with joint destruction driven by both biomechanical and proinflammatory factors.6 In vitro7 and in vivo8 animal models elucidate specific mechanical and biological factors that affect cartilage degradation and tissue changes associated with cartilage growth and remodeling. However, clinical studies are the best vehicle for determining the physiological basis of the biomechanical factors that affect OA pathogenesis and treatment.6,9
Considering the adverse effects of drug therapy, the limited efficacy of surgical intervention in mild-to-moderate cases,10 and the long-term public health benefits of an effective treatment for OA and obesity-related complications,11 we tested the hypothesis that achieving sustained, significant weight loss, with or without increased exercise, would reduce joint loading and inflammation and improve clinical outcomes more than increased exercise alone. This translational study compared the effects of diet-induced weight loss plus exercise (D+E), diet-induced weight loss only (D), and exercise-only (E) interventions on mechanistic outcomes (knee-joint compressive force, IL-6 levels) and clinical outcomes (pain, function, mobility, health-related quality of life [HRQL]) in overweight and obese adults with knee OA.
Intensive Diet and Exercise for Arthritis (IDEA) was a single-blind, single-center, 18-month, randomized controlled trial. Participants were randomized into 1 of 3 groups: D+E, D, or E. We designated E as the comparison group because our work12 indicated that aerobic walking or resistance training should be part of the standard of care for knee OA patients. Interventionists’ responsibilities were limited to exercise and dietary therapy interactions with patients (no data collection). Personnel responsible for data collection without intervention responsibilities were blinded to group assignment. Trial design and rationale are detailed elsewhere.13
IDEA was conducted at Wake Forest University and Wake Forest School of Medicine between July 2006 and April 2011. The study was approved by the human subjects committee of Wake Forest Health Sciences. Informed consent was obtained in writing from all participants.
The sample consisted of ambulatory, community-dwelling persons age 55 years or older with the following: Kellgren-Lawrence14 grade 2 or 3 (mild or moderate) radiographic tibiofemoral OA or tibiofemoral plus patellofemoral OA of one or both knees, pain on most days due to knee OA, a body mass index (BMI) from 27 through 41 (calculated as weight in kilograms divided by height in meters squared), and a sedentary lifestyle (<30 minutes per week of formal exercise for the past 6 months). Participants maintained and adjusted their usual medications as needed with their physicians’ consent. Eligibility, sample size calculations, and screening measurements are detailed elsewhere.13 Race/ethnicity was determined by self-report. Participants chose between white/Caucasian (not Hispanic), black or African American (not Hispanic), Hispanic, Asian or Pacific Islander, American Indian, or Alaskan native. Effort was made to recruit a sample population that was representative of the racial/ethnic demographics of the local area.
Participants were recruited between November 2006 and December 2009. Eligibility was determined by initial phone screen and 2 in-person screening visits.13 A stratified-block randomization method was used to assign all eligible persons to 1 of the 3 intervention groups, stratified by BMI and sex.
The D group received the weight loss intervention, the E group received the exercise intervention, and the D+E group received both.
The goal of this intervention was a mean group loss of at least 10% of baseline weight, with a desired range between 10% and 15%. The diet was based on partial meal replacements, including up to 2 meal-replacement shakes per day (Lean Shake; General Nutrition Centers). For the third meal, participants followed a weekly menu plan and recipes that were 500 to 750 kcal, low in fat, and high in vegetables. Daily caloric intake was adjusted according to the rate of weight change between intervention visits.
The initial diet plan provided an energy-intake deficit of 800 to 1000 kcal/day as predicted by energy expenditure (estimated resting metabolism × 1.2 activity factor) with at least 1100 kcal for women and 1200 kcal for men. The calorie distribution goal was 15% to 20% from protein, less than 30% from fat, and 45% to 60% from carbohydrates, consistent with the Dietary Reference Intakes for Energy and Macronutrients15 and successful weight loss programs.16 As follow-up progressed, fewer meal replacements were consumed. Body weight was monitored weekly or biweekly during nutrition education and behavioral sessions: from months 1 through 6, 1 individual session and 3 group sessions per month, and from months 7 through 18, biweekly group sessions and an individual session every 2 months.
The exercise intervention was conducted for 1 hour on 3 days/week for 18 months. During the first 6 months, participation was center-based. After 6-month follow-up testing and a 2-week transition phase, participants could remain in the facility program, opt for a home-based program, or combine the two. The program consisted of aerobic walking (15 minutes), strength training (20 minutes), a second aerobic phase (15 minutes), and cool-down (10 minutes).
Diet and exercise interventionists were trained in behavioral techniques based on social cognitive theory and group dynamics.17,18 Adherence data were reviewed regularly to identify participants who needed additional counseling. Participants in both the D and E interventions monitored themselves by completing daily logs. A behavioral “toolbox” for participants in the D+E and D groups who had difficulty achieving the weight loss goal included additional individual and group counseling, social support, and incentives.
All participants were tested at baseline, 6 months, and 18 months. An initial symptom-limited, maximum exercise stress test excluded anyone with severe manifestations of coronary heart disease. The Modified Mini-Mental State Exam screened for cognitive deficiencies,19 and persons scoring less than 70 at baseline were ineligible.
Bone-on-bone peak tibiofemoral (knee) compressive force was the primary measure of knee joint loading. Instruments and knee joint compressive force calculations are described in the eMethods in the Supplement and elsewhere.20
Blood samples were collected in the early morning after a 10-hour fast at baseline, 6 months, and 18 months. The 6- and 18-month samples were collected at least 24 hours after the last acute bout of exercise training (D+E and E groups) and sampling was postponed (1-2 weeks after recovery from symptoms) in the event of an acute respiratory, urinary tract, or other infection. All blood was collected, processed, divided into aliquots, and stored at −80°C until analysis.
The inflammation measure was plasma IL-6 in pg/mL. This cytokine is implicated in OA pathogenesis and showed significant improvement with weight loss in the Arthritis Diet and Activity Promotion Trial (ADAPT).21 All samples were measured in duplicate using enzyme-linked immunosorbent assays (Quantikine ELISA kits; R&D Systems) with the average used for data analyses.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale was used to measure self-reported pain.22 Participants indicated on a scale from 0 (none) to 4 (extreme) the degree of pain experienced while performing daily living activities in the last 48 hours due to knee OA. Total scores for the 5 items range from 0 to 20; higher scores indicate greater pain.22,23 Individual scores on the 17 items of the WOMAC self-reported function subscale were added to generate a summary score ranging from 0 to 68; higher scores indicate poorer function. A minimally clinically important difference of at least 20% improvement from baseline is required for both pain and function.24 We used the 36-item short-form (SF-36)25 to measure HRQL using 2 broad summary scores: physical and mental health, scaled from 0 (worst) to 100 (best).
We measured gait speed (m/s) and 6-minute walk distance (m).26 Weight, height, and BMI were obtained at baseline, 6 months, and 18 months using standard techniques. D+E and D participants were weighed at each scheduled nutrition education and behavioral session. Whole body lean mass and fat mass were measured at baseline and 18 months by dual x-ray absorptiometry using a fan-beam scanner (Delphi A; Hologic) and the manufacturer’s recommendations for patient positioning, scanning, and analysis. We used bilateral, posterior-anterior, weight-bearing knee x-rays to identify tibiofemoral OA and sunrise views to identify patellofemoral OA. To visualize the tibiofemoral joint, we used a positioning device to flex knees 15°, with the beam centered on the joint space.
Primary outcomes for IDEA were IL-6 level and knee compressive force. Values for IL-6 were log-transformed for sample size calculations and analyses. Standard deviations were obtained from the ADAPT4 study, which measured the same outcomes in a similar population. The sample size of 150 participants per group was calculated based on both primary outcomes to obtain 80% power to detect a 20% difference in IL-6 group mean ratios at month 18 and a 15% between-group mean difference in knee compressive force at the .008 significance level adjusted for 2 outcomes, 3 treatment groups, and 80% retention. This sample size also provided 80% power for mean differences in secondary outcomes of 2.9 for WOMAC function and 1.0 in WOMAC pain at the .0167 (3 treatment groups) significance level.
Intention-to-treat analyses were conducted with SAS version 9.2 (SAS Institute). Two-sided nominal P values are reported. One-way analyses of variance and χ2 tests addressed differences in baseline characteristics among groups. The effect of the intervention on knee compressive forces, IL-6 levels, WOMAC pain and function, walk speed, 6-minute walk distance, and SF-36 score were determined using mixed model regression analyses adjusted for IDEA stratification factors (BMI, sex, and baseline values). Analyses included all follow-up data, and intervention effects were estimated at each follow-up visit. A contrast for the intervention effect at 18 months was tested in each model, using the E group as the reference group. Effect sizes were calculated by subtracting the E mean from the D+E and D least-squared means and dividing by their pooled standard deviations. Unadjusted percent change at 18 months for each group was obtained by subtracting the baseline mean from the 18-month mean and dividing by the baseline mean. When the overall 18-month P value was ≤.025 for the primary outcomes, specific pairwise differences were noted, with the significance level adjusted for 6 comparisons (P ≤ .008). For the secondary outcomes, the significance levels were .05 and .0167 (3 treatment groups).
To assess whether our results were biased because of missing data, we performed a sensitivity analysis using multiple imputation for all 454 randomized individuals. We imputed 50 fully observed data sets with complete data at 6- and 18-month visits, analyzed each data set using our previously stated analytic protocol, and aggregated the results. The imputation and aggregation were performed using PROC MI and PROC MIANALYZE, respectively, in SAS version 9.3. Data from the multiple imputation analyses are presented in the “Results” section and the intention-to-treat completers-only analyses are shown in the Supplement.
The dose-response relationship between each outcome variable and continuous and categorical weight change (<5%, 5%-9.9%, ≥10%) was assessed using mixed model regression analyses, controlling for BMI, sex, baseline values, and group assignment. The weight loss categories reflect the weight loss goals of 5% or more for ADAPT and 10% or more for IDEA.4,13
Figure 1 and Table 1 show eligibility criteria, characteristics, and progress of the randomized cohort. Of the 454 participants, 399 (88%) completed the study (returned for 18-month follow-up). Retention did not differ significantly among the groups (E, 89%; D, 85%; D+E, 89%), and noncompleters did not differ significantly from completers in terms of age, sex, race, number of comorbidities, initial radiographic score, knee pain, or physical function.
Adherence to exercise (number of sessions completed/number scheduled) for the E group was 66% for the first 6 months and 54% for 18 months; for the D+E group, it was 70% and 58%, respectively. Adherence to the diet intervention (number of individual and class sessions attended/number scheduled) was 61% for the D group and 63% for the D+E group. Three nonserious adverse events related to the trial included a muscle strain and 2 trips/falls during exercise sessions that resulted in soreness and bruising. The external safety monitor determined that 10 serious adverse events were unrelated to the study (eTable 1 in the Supplement). Seven participants underwent surgery during the study: E group participants had 1 knee surgery and 3 knee replacements; the D+E group had 1 foot surgery, 1 gallbladder surgery, and 1 hip replacement. All but the patient who had knee surgery returned to the study after surgery.
Both diet groups (D and D+E) lost significantly (P < .001) more weight than the E group (Table 2). The D group lost 8.9 kg (9.5%) over 18 months; the mean loss in the D+E group was 10.6 kg (11.4%). Neither group regressed toward baseline values (eFigure in the Supplement). The E group lost 1.8 kg, or 2.0% of baseline body weight. At baseline, 79.3% of all participants had a BMI of 30 or greater. At 18 months, this was reduced to 55.5%, including 69.0% in the E group, 54.6% in the D group, and 43.3% D+E participants.
Total fat mass was significantly less in both diet groups relative to the E group after 18 months (P < .001). Fat mass remained essentially unchanged (−0.4 kg) in the E group, while decreasing 6.5 kg (18%) and 4.8 kg (13%) at 18 months in the D+E and D groups, respectively. The D+E and D groups lost significantly more lean mass than the E group (P < .001), but the percentage of lean mass at 18 months did not differ among the 3 groups.
Evaluation of peak knee compressive force (the biomechanical outcome measure of joint loading) at 18 months demonstrated that the E group had decreased joint loading by 148 N (5%), the D group by 265 N (10%), and D+E by 230 N (9%) (Table 3 and Table 4). Of the pairwise between-group comparisons, the E vs D comparison had the greatest difference in compressive force of 200 N (95% CI, 55-345; P = .007). The differences between the E vs D+E groups and the D vs D+E groups were not significant (Table 5).
Plasma IL-6 level also differed significantly among the groups (P = .008); pairwise between-group comparisons revealed that the differences in the D+E and D groups relative to E were 0.39 pg/mL (95% CI, −0.03 to 0.81; P = .007) and 0.43 pg/mL (95% CI, 0.01 to 0.85; P = .006), respectively (Table 3, Table 4, and Table 5).
Pairwise between-group comparisons of WOMAC pain and function at 18 months revealed that the D+E group had less pain relative to the E (mean score, 1.02; 95% CI, 0.33-1.71; P = .004) and D (1.13; 95% CI, 0.44-1.82; P = .001) groups (Table 5, Figure 2). Post hoc analysis revealed that 38% of the D+E group reported little or no pain after 18 months with scores of 0 or 1 compared with 20% and 22% of the participants in the D and E groups, respectively.
Pairwise between-group comparisons revealed that WOMAC function score was significantly better in the D+E group relative to the E group (mean, 4.29; 95% CI, 2.07-6.50;P < .001). Similarly, D+E participants had better function than D participants (3.30; 95% CI, 1.09-5.51, P = .003). The E vs D comparison showed no significant difference (Table 5).
At 18 months, the D+E group walked 0.04 m/s faster relative to the E group (95% CI, −0.07 to −0.02; P = .003). The differences between E vs D and D vs D+E comparisons were not significant. The 6-minute walk distance was 21.3 m farther in the D+E group relative to the E group (95% CI, −36.3 to −6.4; P = .005). The D+E group also walked 41.5 m farther than the D group (95% CI, −56.4 to −26.6; P < .001), and E participants walked further than D participants (20.2 m; 95% CI, 5.0 to 35.4; P = .009). The difference in the SF-36 physical subscale was 2.81 units in D+E relative to the E group (95% CI, −4.76 to −0.86; P = .005). Changes in the SF-36 mental subscale did not reach significance between any groups (Table 5).
Results from the intention-to-treat completers-only analyses that did not use multiple imputations are shown in eTables 2 and 3 in the Supplement. Pairwise comparisons for knee joint compressive load, IL-6 level, pain, and function were statistically unchanged between the intention-to-treat and multiple imputation analyses. Comparisons between D+E and E for 6-minute walk distance and SF-36 physical subscale reached statistical significance only in the multiple imputation analysis (D+E was better than E; P = .005).
We examined the relationship of percent weight change to 18-month mean (SE) mechanistic and clinical outcomes adjusted for intervention, BMI, sex, and baseline values. Independent of group assignment, the cohort was divided into 3 categories based on 18-month weight loss: high, −32.5% to −10.1%; medium, −9.9% to −5.0%, and low, −4.9% to +9.9%. We found significant weight change dose-response effects in knee compressive force, IL-6 level, pain, and function; participants in the high category had significantly lower joint loads, less systemic inflammation and pain, and better function at 18 months (eTable 4 in the Supplement).
In this translational study of weight loss and exercise among overweight and obese adults with knee OA, we found that after 18 months, mean weight loss was greater in the D+E group and the D group compared with the E group. In addition, when compared with the E group, the D+E group had less inflammation, less pain, better function, faster walking speed, and better physical HRQL.
Peak knee compressive forces decreased and walking speeds increased in all 3 groups after the 18-month intervention period. In pairwise between-group comparisons, peak knee compressive forces were 200 N per step less in the D group than in the E comparator group (Table 5). The clinical importance of this difference is unknown, although it appears that weight loss reduces knee-joint loading even as preferred walking speed increases.
Whether inflammation constitutes a separate OA disease pathway or instead is the downstream result of chronic excessive biomechanical stress is debated.6,27 Systemic inflammation markers, including IL-6, distinguished patients with knee or hip OA from controls,28 and higher systemic levels of IL-6 have been associated with increased odds of developing knee OA.29 Diffusion of such cytokines from the synovial fluid into the cartilage could contribute to cartilage matrix loss by stimulating chondrocyte catabolic activity and inhibiting anabolic activity.6,30 In addition to these direct effects on the joint, inflammatory mediators can affect muscle function and lower the pain threshold.31 IL-6 concentrations less than 2.5 pg/mL have been shown to reduce the risk of mobility disability and improve markers of metabolic syndrome.32 Participants in all 3 groups exceeded this level (mean, 3.1 pg/mL) at baseline, with significant improvements in D+E and D relative to E at 18-month follow-up. Our study was powered to detect a 15% and 20% difference in knee compressive force and IL-6 level but found differences of approximately 8% and 14%, respectively. Results need to be interpreted with this in mind.
With regard to pain, between-group differences in WOMAC score were 1.02 and 1.13 units in the D+E vs E and the D+E vs D groups, with D+E having less pain. Hence, the clinical significance of 1.02-point and 1.13-point between-group differences in the WOMAC pain scale remains uncertain.33
Post hoc analysis revealed that nearly 40% of D+E participants had WOMAC pain scores of 0 or 1 (no or little pain) at 18-month follow-up compared with 20% of the D group and 22% of the E group; pain worsened from baseline in 10% of the D+E group compared with 22% in the D group and 28% in the E group. The D group, which had similar decreases in joint loads and inflammation, experienced only half the D+E pain reduction. Reasons for this finding are unclear. The pain reduction in the E group, despite increased joint loads, inflammation, and walk speed, may indicate psycho-physiological effects of exercise on the central34 and peripheral nervous systems.35
Patients in our cohort reported relatively mild pain at baseline (averaging 6.5 on a 0-20 scale), similar to participants in previous long-term OA clinical trials.4,5,36 This entry level may have been an advantage because lack of adherence due to extreme pain was uncommon, but it left little room for improvement.
Despite use of an active comparison group with level 1 evidence of efficacy,37 the D+E group had better clinical outcomes (ie, pain, function, and mobility). Adherence to exercise for the D+E and E groups was 70% and 66%, respectively, during the first 6 months of center-based activity. As participants incorporated home-based exercise after month 6, adherence decreased to 58% and 54% at 18 months. The D+E group improvement in function and mobility was modest but significantly greater than either the D or E group and greater than that achieved by the ADAPT D+E group.4 Improvements also exceeded those observed in a randomized controlled trial that compared a very low-energy diet with an attention control group5 in which function improved in the diet group at 3-month follow-up but regressed toward baseline values by 12 months. We attribute these results to challenging yet attainable weight loss and exercise goals with a social cognitive behavioral framework.
Walk speed and 6-minute walk distance, measures of mobility, were below normative values for healthy older adults at baseline.38,39 At follow-up at 18 months, the D+E group demonstrated significant pairwise differences relative to the E and D groups (Table 5). Himann et al38 found that walking speed decreased 1% to 2% per decade of adult life until age 62 years, when the decline was 12% to 16% per decade. The cohort in our study reversed this trend by increasing their walking speed and 6-minute walk distance, D+E participants significantly more than the E and D groups. These improvements, in part, may have been due to the significant reduction in knee pain. The D+E group significantly improved the physical health dimension of HRQL relative to the E group with a pairwise difference of 2.81 and an improvement from baseline of 8 units. A minimally important improvement from baseline of 4.11 in the physical subscale has been reported for patients with psoriatic arthritis.40 There were no between-group differences in mental health subscale scores.
A multiple imputation analysis revealed minimal differences from our original intention-to-treat analysis, indicating the strength of the primary analysis. This was due to the low drop-out rate relative to similar studies.12,41 Drop-out did not occur differentially with respect to randomization group, sex, or baseline BMI (P > .05).
Independent of group assignment, participants who lost 10% or more of body weight improved function and reduced knee compressive force, systemic IL-6 concentrations, and pain more than those who lost 5% to 9.9% or less than 5% of their baseline weight. These data are consistent with the National Institutes of Health recommendation for overweight and obese adults to lose 10% of baseline weight as an initial goal.11 Weight loss programs for older adults are not without risks. In addition to fat mass, weight loss reduces lean mass, which is associated in older adults with muscle weakness, greater risk of falls and injury, and loss of independence and mobility, although exercise can attenuate it.42 The D+E and D groups lost substantial fat mass (D+E, −10.6 kg [−18%]; D, −8.9 kg [−13%]) and −4.7 kg (−9%) and −4.2 kg (−8%), respectively, of lean mass. However, relative to total body weight at 18 months, lean mass actually increased 3% in the D+E group and 2% in the D group.
This study has several limitations. Patients in this study had mild-to-moderate radiographic knee OA at baseline (Kellgren-Lawrence scores of 2-3) and similar levels of knee pain. Whether patients with more severe knee OA (Kellgren-Lawrence score of 4) and higher levels of pain would benefit from this long-term intervention is unknown. The musculoskeletal model used to calculate knee compressive forces has several limitations. Several knee ligaments are not included, it assumes that the hip flexors and hip abductors do not co-contract during stance, and its grouped muscle model design cannot distinguish between smaller muscle anatomical units. Nonetheless, we have used this model previously,20,43- 45 and as we recently demonstrated,20 our muscle and joint force predictions are in agreement with those based on a variety of other models46,47 and from measured forces from instrumented knee joint prostheses.48,49 The IDEA trial also benefited from its single-site design, as single-site studies tend to have larger treatment effects than multicenter trials.50
Osteoarthritis and other obesity-related diseases place an enormous physical and financial burden on the US health care system.51 The estimated 97 million overweight and obese Americans are at substantially higher risk for many life-threatening and disabling diseases, including OA.11 The findings from the IDEA trial data suggest that intensive weight loss may have both anti-inflammatory and biomechanical benefits; when combining weight loss with exercise, patients can safely achieve a mean long-term weight loss of more than 10%, with an associated improvement in symptoms greater than with either intervention alone.
Among overweight and obese adults with knee OA, after 18 months, participants in the D+E and D groups had more weight loss and greater reductions in IL-6 levels than those in the E group, those in the D group had greater reductions in knee compressive force than those in the E group, and those in the D+E group had less knee pain and better function than those in the D and E groups and improved physical HRQL than those in the E group.
Corresponding Author: Stephen P. Messier, PhD, J. B. Snow Biomechanics Laboratory, Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC 27109 (email@example.com).
Author Contributions: Dr Messier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Messier, Mihalko, Legault, Miller, Nicklas, DeVita, Williamson, Carr, Loeser.
Acquisition of data: Messier, Legault, Nicklas, Williamson, Carr, Guermazi, Loeser.
Analysis and interpretation of data: Messier, Legault, Miller, Nicklas, DeVita, Beavers, Hunter, Lyles, Eckstein, Williamson, Carr, Guermazi, Loeser.
Drafting of the manuscript: Messier, Mihalko, Legault, Nicklas, DeVita, Hunter, Lyles, Williamson, Loeser.
Critical revision of the manuscript for important intellectual content: Messier, Mihalko, Legault, Miller, Nicklas, DeVita, Beavers, Hunter, Lyles, Eckstein, Williamson, Carr, Guermazi, Loeser.
Statistical analysis: Messier, Legault, Beavers.
Obtained funding: Messier, Mihalko, Legault, Miller, DeVita, Williamson, Carr, Loeser.
Administrative, technical, or material support: Messier, Legault, DeVita, Beavers, Hunter, Lyles, Eckstein, Williamson.
Study supervision: Messier, Mihalko, Legault, Miller, Nicklas, Lyles, Williamson, Carr, Guermazi, Loeser.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Messier reported receiving grants from the US Army, giving expert testimony for Anspach Meeks Ellenberger, receiving payments for lectures from the Michigan Arthritis Collaboration and Boston University, and receiving travel expenses from the Hospital for Special Surgery Osteoarthritis Summit. Dr Legault reported receiving payment for lectures from Charité University in Berlin. Dr DeVita reported consulting with Wake Forest personnel on knee biomechanics and receiving grants from the Department of Defense and the National Institutes of Health (NIH). Dr Beavers reported receiving grants from the NIH. Dr Hunter reported serving on the board of the Osteoarthritis Research Society International; receiving grants from the National Health and Medical Research Council, Australian Research Council, and the NIH; and receiving royalties from DonJoy. Dr Lyles reported receiving a grant from the NIH. Dr Eckstein reported receiving a grant from the NIH; consulting fees from MerckSerono, Novartis, Abbott, Perceptive, Bioclinica; serving on a speakers’ bureau for Synthes and Medtronic; owning stock from Chondrometrics; and receiving travel expenses from MerckSerono. Dr Guermazi reported serving as a consultant for Genzyme, Astra-Zeneca, Novartis, MerckSerono, TissueGene, and sanofi-aventis and owning stock from Boston Imaging Core Lab. No other disclosures were reported.
Funding/Support: Support for this study was provided by grants from the National Institutes of Health—R01 AR052528-01 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, P30 AG21332 from the National Institute on Aging, M01-RR00211 from the National Center for Research Resources—and by General Nutrition Centers.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, analysis, and interpretation of data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the IDEA research staff and the IDEA participants for their important contributions. The participants did not receive compensation for their contributions, and the staff were not compensated besides their salaries.